14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $81.00 $93.35 Thursday, 25th Apr 2024 BMRN stock ended at $82.17. This is 9.90% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 7.14% from a day low at $81.00 to a day high of $86.78.
90 days $81.00 $94.15
52 weeks $76.02 $99.55

Historical BioMarin Pharmaceutical Inc. prices

Date Open High Low Close Volume
Apr 25, 2024 $86.26 $86.78 $81.00 $82.17 7 882 415
Apr 24, 2024 $92.69 $93.02 $91.01 $91.20 1 558 345
Apr 23, 2024 $90.03 $92.22 $89.99 $92.06 1 268 430
Apr 22, 2024 $89.46 $89.81 $88.89 $89.49 1 233 796
Apr 19, 2024 $89.67 $90.18 $88.29 $88.63 1 743 531
Apr 18, 2024 $90.25 $91.20 $89.78 $90.07 925 981
Apr 17, 2024 $91.14 $91.53 $90.02 $90.47 1 226 760
Apr 16, 2024 $90.93 $91.78 $90.16 $90.87 1 207 251
Apr 15, 2024 $92.58 $93.35 $90.97 $91.51 1 906 869
Apr 12, 2024 $91.26 $93.26 $91.09 $92.22 2 343 767
Apr 11, 2024 $90.99 $91.59 $89.35 $91.46 2 045 255
Apr 10, 2024 $88.38 $90.41 $87.79 $90.21 2 179 966
Apr 09, 2024 $87.35 $89.19 $87.35 $88.98 1 151 522
Apr 08, 2024 $87.00 $88.11 $86.96 $87.28 1 063 248
Apr 05, 2024 $86.46 $87.21 $86.02 $86.95 798 088
Apr 04, 2024 $86.78 $88.13 $86.63 $86.89 1 138 947
Apr 03, 2024 $86.48 $87.72 $86.48 $86.78 1 103 456
Apr 02, 2024 $86.25 $86.94 $85.62 $86.80 863 643
Apr 01, 2024 $86.98 $87.31 $86.09 $87.10 616 432
Mar 28, 2024 $88.34 $88.66 $86.65 $87.34 928 414
Mar 27, 2024 $88.18 $88.74 $87.94 $88.61 960 055
Mar 26, 2024 $86.94 $87.86 $86.52 $87.74 1 319 341
Mar 25, 2024 $84.70 $86.99 $84.70 $86.52 1 385 930
Mar 22, 2024 $84.35 $85.29 $83.90 $85.13 859 209
Mar 21, 2024 $84.99 $85.25 $83.84 $84.11 886 926
Click to get the best stock tips daily for free!

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT